louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03543709: Evaluation of Fibromyalgia With Disease Activity and Clinical Findings in Women With Behçet's Disease
Official title: Evaluation of Fibromyalgia With Disease Activity and Clinical Findings in Women With Behçet's Disease in Province Bursa
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Behcet's Disease
Fibromyalgia
Keywords: Behcet's disease
Fibromyalgia
Disease activity
Lead sponsor: Bursa Yüksek İhtisas Education and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2018-06-01
Enrollment: 72
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Women diagnosed with Behcet disease according to international study group criteria, between age 18-75, which are not pregnant and which were not previously diagnosed with diabetes mellitus or chronic renal failure.

Brief summary: In the literature, the relationship between fibromyalgia and disease activity has been assessed in a few studies without discrimination between women and men.In this study, it was aimed to evaluate the relationship between fibromyalgia and disease activity in women with Behçet's disease.

Detailed description: There are only a few studies in the literature evaluating the association of fibromyalgia with disease activity and clinical findings in Behçet's disease. In the literature, the relationship between fibromyalgia and disease activity has been assessed without discrimination between women and men. Behçet's disease is more active in men and fibromyalgia is more frequent in women. Evaluating the relationship between fibromyalgia and disease activity in Behçet's disease without gender discrimination may not be objective.There is not any study in literature evaluating relationship between fibromyalgia and disease activity in women with Behçet's disease.In this study, it was aimed to evaluate the relationship between fibromyalgia and disease activity in women with Behçet's disease.

Eligibility criteria: Inclusion Criteria:

* Women diagnosed with Behcet disease according to international study group criteria
* Patients older than 18
* Patients younger than 75

Exclusion Criteria:

* Participants which were previously diagnosed with diabetes mellitus
* Participants which were previously diagnosed with chronic renal failure
* Pregnant women

Primary outcomes:
measure: Fibromyalgia 2013 criteria
timeFrame: 5 months
Secondary outcomes:
measure: Behcet's disease current activity form
timeFrame: 5 months
Other outcomes:
Locations:
city: Bursa
country: Turkey
facility: Koray
Study officials:
References:
Clinical trial NCT00928109: UCAN: Uniting Couples in the Treatment of Anorexia Nervosa
Official title: Innovative Trial for the Treatment of Anorexia Nervosa in Late Adolescence and Adulthood
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anorexia Nervosa
Keywords: eating disorders
couples therapy
Lead sponsor: University of North Carolina, Chapel Hill
Sponsor class: OTHER
Collaborators: name: National Institute of Mental Health (NIMH)
First posted: 2009-06-25
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: UCAN is a research program funded by the National Institute of Mental Health and is part of the UNC Eating Disorders Program. UCAN aims to help couples work together in the treatment of anorexia nervosa. Couples participate in UCAN over a period of six months and return for follow-up treatment three months after the end of the original six-month period. Patients receive weekly individual therapy, monthly psychiatry consultations, monthly dietary consultations in addition to being randomized to one of two types of weekly couples therapy. Participation in UCAN can help participants gain new confidence in facing anorexia as a team and can help us understand how best to involve partners in the treatment of eating disorders.

Detailed description: Patients receive comprehensive eating disorder treatment at the UNC Eating Disorders Outpatient Program in addition to couples therapy. Eligibility: Participants may be eligible if they are 18 or older, have anorexia nervosa and are currently living with a partner with whom they have been in a committed relationship for at least a year. The partner must also be willing to enter treatment.

Eligibility criteria: Inclusion Criteria:

* Anorexia Nervosa,
* 18 years or older,
* BMI 16 or higher,
* In a committed relationship with a partner for 1 year or longer and currently living together.

Exclusion Criteria:

* Alcohol or drug dependence in past year,
* Current significant suicidal ideation,
* Developmental disability that would impair the ability of the participant to benefit from the intervention,
* Psychosis,
* BMI less than 16.

Primary outcomes:
measure: Eating disorder behavior
timeFrame: 9 months
Secondary outcomes:
measure: Couple Satisfaction
timeFrame: 9 months
Other outcomes:
Locations:
city: Chapel Hill
country: United States
facility: UNC Chapel Hill
state: North Carolina
Study officials:
affiliation: UNC Chapel Hill Department of Psychiatry
name: Cynthia M Bulik, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: UNC Chapel Hill Department of Psychology
name: Donald Baucom, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04973709: Prevalence of Dementia and Delirium in Outpatient Clinics (DESTAN Trial)
Official title: Gulhane Training and Research Hospital
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Delirium in Old Age
Delirium Superimposed on Dementia
Delirium With Dementia
Keywords: Delirium
Dementia
Mortality
Etiology
Outpatient
Lead sponsor: Gulhane Training and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2021-07-22
Enrollment: 714
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Community-dwelling older adults (65 years and older)

Brief summary: The aim of this study is to assess the prevalence and etiologic risk factors of delirium in outpatient geriatric patients and also hospitalized patients.

Detailed description: This study aimed to investigate the frequency of delirium and examines the association between delirium and other possible risk factors and prognostic factors (dementia etc.)

Eligibility criteria: Inclusion Criteria:

* We included all 65 years older patients who evaluated according to a comprehensive geriatric assessment that is consistently performed during admission to the outpatients' clinic of the hospital.

Exclusion Criteria:

* Exclusion criteria were serious psychiatric disorders such as schizophrenia or major depression.

Primary outcomes:
measure: frequency of Mortality
timeFrame: 1 year fellow-up
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Gulhane training and research hospital
Study officials:
affiliation: Saglik Bilimleri Universitesi
name: Mehmet Naharcı
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06393309: Levetiracetam Versus Valproate in Idiopathic Generalized Epilepsy
Official title: Investigation of Long-term Outcome of Levetiracetam and Valproate in Treatment of Idiopathic Generalized Epilepsy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Treatment of Idiopathic Generalized Epilepsy
Keywords: Levetiracetam
Valproate
Idiopathic generalized epilepsy
Lead sponsor: Mazandaran University of Medical Sciences
Sponsor class: OTHER
First posted: 2024-05-01
Enrollment: 169
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adult patients with idiopathic generalized epilepsy (juvenile myoclonic epilepsy or generalized tonic-clonic seizure alone) who are on monotherapy with levetiracetam or sodium valproate

Brief summary: This study aimed to compare the long-term efficacy and safety of levetiracetam and valproate in treatment of idiopathic generalized epilepsy.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of juvenile myoclonic epilepsy or generalized tonic-clonic seizure alone
* Regular monotherapy with levetiracetam or sodium valproate

Exclusion Criteria:

* Poor drug adherence
* Pregnancy

Primary outcomes:
measure: Seizure free rate
timeFrame: 1 to 5 years
measure: Time to first seizure
timeFrame: 1 to 5 years
Secondary outcomes:
measure: Retention rate
timeFrame: 1 to 5 years
measure: Time to withdrawal
timeFrame: 1 to 5 years
Other outcomes:
Locations:
city: Sari
country: Iran, Islamic Republic of
facility: Bu Ali Sina Hospital
state: Mazandaran
Study officials:
References:
Clinical trial NCT02542709: The Use of Noninvasive Brain Stimulation in Post-traumatic Stress Disorder
Official title: The Use of Noninvasive Brain Stimulation in Post-traumatic Stress Disorder
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Post-traumatic Stress Disorder
Lead sponsor: Laval University
Sponsor class: OTHER
First posted: 2015-09-07
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this trial is to study the effect of noninvasive brain stimulation in adults with post-traumatic stress disorder.

Detailed description: The purpose of this trial is to study the effect of noninvasive brain stimulation on symptoms severity in adults with post-traumatic stress disorder.

Eligibility criteria: Inclusion Criteria:

* 18-60 years old

Exclusion Criteria:

* Transcranial magnetic stimulation ineligibility

Primary outcomes:
measure: Severity of symptoms on the following clinical scale: PTSD symptoms as assessed by the Modified PTSD Symptom Scale (MPSS-SR)
timeFrame: 2 months
Secondary outcomes:
measure: Severity of symptoms on the following clinical scale: anxiety symptoms as assessed by the Beck Anxiety Inventory (BAI)
timeFrame: 2 months
measure: Severity of symptoms on the following clinical scale: depression symptoms as assessed by the Beck Depression Inventory (BDI)
timeFrame: 2 months
Other outcomes:
Locations:
city: Quebec
country: Canada
facility: IRDPQ
Study officials:
References:
Clinical trial NCT02083809: Effects of Oxytocin on Bleeding Outcomes During Dilation and Evacuation
Official title: A Randomized Double-blinded Controlled Trial Comparing Dilation and Evacuation Outcomes With and Without Oxytocin Use
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Abortion
Dilation and Evacuation
Hemorrhage
Blood Loss
Lead sponsor: University of Hawaii
Sponsor class: OTHER
Collaborators: name: Society of Family Planning
name: University of Washington
First posted: 2014-03-11
Enrollment: 166
Sex: FEMALE
Minimum age (years): 14
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Currently, there is very little research to identify ways to decrease blood loss during D\&E (dilation and evacuation) procedures. The objective is to determine whether routine use of intravenous oxytocin will improve bleeding outcomes at the time of D\&E at 18-24-weeks gestation. To evaluate the hypothesis, investigators will perform a randomized, double-blinded, placebo-controlled trial. The patient will be followed until discharged from the postoperative care unit during which time patient satisfaction, pain score and postoperative bleeding will be assessed.


Eligibility criteria: Inclusion Criteria:

* Requesting pregnancy termination
* Intrauterine pregnancy at 18- to 24-weeks gestation
* Gestational-age to be confirmed by ultrasound
* Patients with fetal anomaly or intrauterine fetal demise that occurred at 18- to 24-weeks gestation
* Willing and able to understand and sign written informed consents in English or Spanish and comply with study procedures

Exclusion Criteria:

* Ultrasound findings suggestive of placenta accreta
* Patients requiring preoperative misoprostol

Primary outcomes:
measure: Rate at Which Providers Intervene to Control Blood Loss During D&E Procedures.
timeFrame: During surgical procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Honolulu
country: United States
facility: University of Hawaii
state: Hawaii
city: Seattle
country: United States
facility: University of Washington
state: Washington
Study officials:
References:
citation: Whitehouse K, Tschann M, Soon R, Davis J, Micks E, Salcedo J, Savala M, Kaneshiro B. Effects of Prophylactic Oxytocin on Bleeding Outcomes in Women Undergoing Dilation and Evacuation: A Randomized Controlled Trial. Obstet Gynecol. 2019 Mar;133(3):484-491. doi: 10.1097/AOG.0000000000003104.
Clinical trial NCT03178409: Combined HCC-MFCCC
Official title: Survival After Hepatectomy for Combined Hepatocellular Cholagiocarcinoma
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Liver Carcinoma
Hepatocellular Carcinoma
Cholangiocarcinoma
Surgery
Lead sponsor: University of Milan
Sponsor class: OTHER
First posted: 2017-06-06
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients affected by cHCC-MFCCC, or HCC or MFCCC.

Brief summary: Combined hepatocellular and mass-forming cholangiocarcinoma (cHCC-MFCCC) is a rare tumor. The aim of this study was the analysis of the outcome comparing such tumor with classic hepatocellular carcinoma (HCC) and mass-forming cholangiocarcinoma (MFCCC).

Detailed description: The institutional prospectively maintained database was queried, and 20 patients with cHCC-MFCCC were identified. A 2:1 match was performed with 40 patients operated in the same period for HCC, and with 40 operated for MFCCC. Only T1 or T2 patients N0 M0 were considered. Primary endpoint was the overall survival (OS) and disease-free survival (DFS).

Eligibility criteria: Inclusion Criteria:

* positive histology for cHCC-MFCCC, HCC, and MFCCC
* complete clinical, surgical, pathological and follow-up data.

Exclusion Criteria:

* patients preoperatively treated with chemotherapy, radiofrequency ablation or trans-arterial therapies were excluded.
* patients operated for recurrent disease and/or with non-radical surgery
* patients with missing data were also excluded

Primary outcomes:
measure: Survival analysis
timeFrame: From 3 months after surgery up to 60 months after surgery
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05453409: Study on Clinical Features, Treatment Mode and Survival of Sarcoma
Official title: A Single-center Retrospective Study of Clinical Features, Treatment Patterns, and Survival of Sarcomas
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Sarcoma
Lead sponsor: Henan Cancer Hospital
Sponsor class: OTHER_GOV
First posted: 2022-07-12
Enrollment: 6000
Sex: ALL
Minimum age (years): 6
Maximum age (years): 99
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Sarcoma patients receiving inpatient treatment in Henan Tumor Hospital.

Brief summary: The clinical data of all eligible patients who received chemotherapy, radiotherapy, targeted therapy, immunotherapy, interventional therapy and surgery in Henan Tumor Hospital from June 1, 2012 to May 30, 2022 were retrospectively collected.

Detailed description: This study was a single-center retrospective clinical study, which retrospectively collected the clinical data of all eligible patients receiving chemotherapy, radiotherapy, targeted therapy, immunotherapy, interventional therapy and surgical treatment in Henan Tumor Hospital from June 1, 2012 to May 30, 2022. The efficacy, recurrence and survival of various treatments were collected.

Eligibility criteria: Inclusion Criteria:

No age limit, male or female. A certain subtype of sarcoma was diagnosed by pathology in our hospital. Has received at least one hospitalization in this hospital. Target lesions can be evaluated according to solid tumor efficacy evaluation criteria (RECIST; Version 1.1) Measure diameter changes.

Complete follow-up data.

Exclusion Criteria:

No clear pathology. Incomplete follow-up data.

Primary outcomes:
measure: Progression-free survival
timeFrame: Up to approximately 24months
measure: Overall survival
timeFrame: Up to approximately 120months
Secondary outcomes:
Other outcomes:
Locations:
city: Zhengzhou
country: China
facility: Department of Bone and Soft Tissue ,Henan Cancer Hospital
state: Henan
Study officials:
References:
Clinical trial NCT06603909: Health Outcomes of Nasopharyngeal Carcinoma Patients Three Years After Treatment by the AI-assisted Home Enteral Nutrition Management
Official title: Health Outcomes of Nasopharyngeal Carcinoma Patients Three Years After Treatment by the AI-assisted Home Enteral Nutrition Management
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cancer, Carcinoma
Artificial Intelligence (AI)
Nutrition
Lead sponsor: Changsha Medical University
Sponsor class: OTHER
First posted: 2024-09-19
Enrollment: 500
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: You have completed the current stage of cancer treatment, after which you need to check regularly and pay attention to nutrition. So we started this study to see if AI could help with nutrition management. Main options: Option 1: Use AI to assist nutrition management; Option 2: Contact the nutritionist team of the hospital for nutrition management according to your own situation. Option 3: Do not adopt the first two management methods. Special Statement: Please choose; Cancer screening data is used for statistical analysis, but does not reveal any personal privacy.


Eligibility criteria: Inclusion Criteria:

* Malignant tumor patient

Exclusion Criteria:

* no

Primary outcomes:
measure: Survival Rate
timeFrame: three years after treatment
measure: Local Recurrence Rate
timeFrame: three years after treatment
Secondary outcomes:
measure: DNA positive rate of Epstein-Barr(EB) virus
timeFrame: three years after treatment
measure: Body mass index
timeFrame: three years after treatment
Other outcomes:
Locations:
city: Zhengzhou
country: China
facility: First Affiliated Hospital of Zhengzhou University
Study officials:
References:
citation: Kulkarni S, Seneviratne N, Baig MS, Khan AHA. Artificial Intelligence in Medicine: Where Are We Now? Acad Radiol. 2020 Jan;27(1):62-70. doi: 10.1016/j.acra.2019.10.001. Epub 2019 Oct 19.
citation: Mundi MS, Mohamed Elfadil O, Olson DA, Pattinson AK, Epp LM, Miller LD, Seegmiller SL, Schneckloth JM, Baker MR, Abdelmagid MG, Patel A, Wescott BA, Elder LS, Hagenbrock MC, Sefried LE, Hurt RT. Home enteral nutrition: A descriptive study. JPEN J Parenter Enteral Nutr. 2023 May;47(4):550-562. doi: 10.1002/jpen.2498. Epub 2023 Apr 12.
citation: Bischoff SC, Austin P, Boeykens K, Chourdakis M, Cuerda C, Jonkers-Schuitema C, Lichota M, Nyulasi I, Schneider SM, Stanga Z, Pironi L. ESPEN practical guideline: Home enteral nutrition. Clin Nutr. 2022 Feb;41(2):468-488. doi: 10.1016/j.clnu.2021.10.018. Epub 2021 Nov 24.
citation: Muscaritoli M, Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, Hutterer E, Isenring E, Kaasa S, Krznaric Z, Laird B, Larsson M, Laviano A, Muhlebach S, Oldervoll L, Ravasco P, Solheim TS, Strasser F, de van der Schueren M, Preiser JC, Bischoff SC. ESPEN practical guideline: Clinical Nutrition in cancer. Clin Nutr. 2021 May;40(5):2898-2913. doi: 10.1016/j.clnu.2021.02.005. Epub 2021 Mar 15.
Clinical trial NCT02038309: Persistent Platelet Reactivity in Acute Coronary Syndrome
Official title: Persistent Platelet Reactivity in Acute Coronary Syndrome
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Coronary Syndrome
Keywords: Acute coronary syndrome
persistent platelet reactivity
Lead sponsor: Hopital Lariboisière
Sponsor class: OTHER
First posted: 2014-01-16
Enrollment: 106
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Acute coronary syndrome

Brief summary: Study of persistent platelet reactivity during acute coronary syndrome. Patients are included at admission to the hospital. Platelet aggregation is evaluated by platelet function testing after blood sampling during hospitalization. No changes in treatment is planned.

Detailed description: Blood samples are performed on day 2 and 4 and collected with usual blood samples and analyzed by the laboratory. Maximal aggregation intensity and velocity are measured by light transmission aggregometry induced by arachidonic acid (AA) or adenosine diphosphate (ADP). Platelet function analyzer will be also used. No changes in treatment in response to the results is planned.

Eligibility criteria: Inclusion Criteria:

* acute coronary syndrome with elevation in troponin

Exclusion Criteria:

* anticoagulant treatment

Primary outcomes:
measure: maximum aggregation intensity
timeFrame: day 2
Secondary outcomes:
measure: Maximum aggregation intensity
timeFrame: Day 2
measure: Maximum aggregation intensity
timeFrame: Chronic phase (day 30 to day 60)
Other outcomes:
measure: Major cardiovascular and cerebrovascular events (MACCE)
timeFrame: one year
measure: microvascular resistance index
timeFrame: Day 1
Locations:
city: Paris
country: France
facility: Department of Cardiology - Lariboisiere Hospital
Study officials:
affiliation: Department of Cardiology - Lariboisiere Hospital - APHP
name: Patrick Henry, MD-PhD
role: STUDY_DIRECTOR
References: